# Bococizumab HIV Evaluation (B-HIVE) Study

> **NCT02524106** · PHASE3 · TERMINATED · sponsor: **University of California, San Francisco** · enrollment: 11 (actual)

## Conditions studied

- Dyslipidemia
- Cardiovascular Disease

## Interventions

- **DRUG:** Bococizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02524106
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Industry won't be moving forward with production of bococizumab
- **Last updated:** 2019-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02524106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02524106, "Bococizumab HIV Evaluation (B-HIVE) Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02524106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*